Daré Bioscience Posts Narrower Q2 Loss

Daré Bioscience (NASDAQ:DARE), a women’s health-focused biopharmaceutical company developing new therapies and devices, announced its second quarter 2025 results on August 14, 2025. The headline news was a negative GAAP revenue figure of $21,172, falling far short of the $280,000 consensus estimate for GAAP revenue. On earnings per share (EPS), the company posted a GAAP loss of $0.45, which was a narrower loss than the expected $0.58 (GAAP). The company demonstrated lower operating expenses compared to Q2 2024, but continued to post steep losses and reported a significant working capital deficit. Overall, the quarter showed important clinical and strategic progress but underscored critical financial risks, with near-term revenue still heavily dependent on upcoming product launches. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. The company has built its business around developing therapies and medical devices specifically addressing women’s health needs such as contraception, sexual health, and menopause symptom management. Its pipeline includes products like Sildenafil Cream for female sexual arousal disorder and Ovaprene, a hormone-free monthly contraceptive device.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool